Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

Gouty tophi, driven by hyperuricemia, bacterial infection, and excessive inflammation, are highly susceptible to rupture, while current therapies fail to simultaneously address these factors, often leading to chronic non‐healing wounds and increased amputation risk. Herein, guided by the pathological features of the gout wound microenvironment, we developed a multifunctional nanoplatform by co‐loading uricase (Uri) and catalytic carbon dots (CDs) onto highly adhesive polydopamine (PDA) nanoparticles. The resulting CDs‐Uri@PDA integrates uric acid (UA) degradation, antibacterial action, and inflammation modulation into a unified three‐in‐one system. Under hyperuricemic conditions, Uri catalyzes UA decomposition to generate localized antibacterial H 2 O 2 at the early stage, while the polyphenolic groups of PDA synergistically enhance the overall antibacterial efficacy and the adhesive matrix protects wounds from external contamination. Subsequently, CDs selectively eliminate residual H 2 O 2 and excessive reactive oxygen species during the inflammatory phase, suppressing inflammatory signaling and promoting wound repair. Through this cascade of stage‐dependent dual‐catalytic regulation, CDs‐Uri@PDA enables sequential therapy of gout wound ulcers and accelerates healing, offering a promising strategy to improve uricase‐based treatments and advance clinical management of gout wounds.